Linked Life Data

9403579

Source:http://linkedlifedata.com/resource/pubmed/id/9403579

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1998-1-8
pubmed:abstractText
Estrogens are reported to provide protection against the development of cardiovascular disease in women, but the mechanisms underlying these effects are not well defined. We hypothesized that estrogen might reduce neural cardiovascular tone. We therefore studied responses to exogenous norepinephrine and norepinephrine spillover in 12 perimenopausal women randomized to 8 weeks of estrogen supplementation (estradiol valerate, 2 mg daily, n=7) or placebo (n=5). Forearm blood flow was measured by venous occlusion plethysmography, and vasoactive agents were infused through a brachial artery cannula in doses that did not influence blood pressure or heart rate. Total body and forearm norepinephrine spillover were measured by radiotracer methodology. Forearm vasoconstrictor responses to norepinephrine (25, 50, and 100 ng/min) were attenuated after estrogen supplementation (P=.002). Vasoconstrictor responses to angiotensin II (8, 16, and 32 ng/min) were unchanged postestrogen. There was a significant reduction in total body spillover of norepinephrine after estrogen supplementation (pre-estrogen, 700+/-152; postestrogen, 439+/-150 ng/min; P<.05), but there was no change after placebo. Total body clearance and forearm spillover of norepinephrine were unchanged by either estrogen or placebo. Estrogen supplementation also significantly decreased both systolic and diastolic blood pressures. Therefore, estrogen supplementation in perimenopausal women selectively attenuates vasoconstrictor responses to norepinephrine and reduces total body norepinephrine spillover, which is an index of sympathetic neural activity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0194-911X
pubmed:author
pubmed:issnType
Print
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1538-43
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:9403579-Analysis of Variance, pubmed-meshheading:9403579-Angiotensin II, pubmed-meshheading:9403579-Blood Glucose, pubmed-meshheading:9403579-Blood Pressure, pubmed-meshheading:9403579-Cholesterol, pubmed-meshheading:9403579-Estradiol, pubmed-meshheading:9403579-Estrogen Replacement Therapy, pubmed-meshheading:9403579-Estrogens, Conjugated (USP), pubmed-meshheading:9403579-Female, pubmed-meshheading:9403579-Follicle Stimulating Hormone, pubmed-meshheading:9403579-Forearm, pubmed-meshheading:9403579-Humans, pubmed-meshheading:9403579-Menopause, pubmed-meshheading:9403579-Metabolic Clearance Rate, pubmed-meshheading:9403579-Norepinephrine, pubmed-meshheading:9403579-Random Allocation, pubmed-meshheading:9403579-Regional Blood Flow, pubmed-meshheading:9403579-Triglycerides, pubmed-meshheading:9403579-Vasoconstriction
pubmed:year
1997
pubmed:articleTitle
Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spillover in perimenopausal women.
pubmed:affiliation
Alfred and Baker Medical Unit and Menopause Clinic, Baker Medical Research Institute and Alfred Hospital, Melbourne, Australia.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't